tbuckley/cabot-search huggingface dataset:
A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures
Authors: Michael Thomas Wong, David Eng Hui Ong, Frances Sheau Huei Lim, Karen Wei Weng Teng, Naomi McGovern, Sriram Narayanan, Wen Qi Ho, Daniela Cerny, Henry Kun Kiaang Tan, Rosslyn Anicete, Bien Keem Tan, Tony Kiat Hon Lim, Chung Yip Chan, Peng Chung Cheow, Ser Yee Lee, Angela Takano, Eng-Huat Tan, John Kit Chung Tam, Ern Yu Tan, Jerry Kok Yen Chan, Katja Fink, Antonio Bertoletti, Florent Ginhoux, Maria Alicia Curotto de Lafaille, Evan William Newell
Journal: Immunity (2016)
New anti-tuberculosis drugs for special populations: a difficult-to-address issue
Authors: Giovanni Sotgiu, Emanuele Pontali, Rosella Centis, Lia D'Ambrosio, Giovanni Battista Migliori
Journal: European Respiratory Journal (2016)

We read with interest correspondence from L. McKenna and L. Ruiz Mingote commenting on the editorial by Pontali et al . [1] "Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence". Their core message is the lack of availability of the new anti-tuberculosis (TB) drugs ( i.e. bedaquiline and delamanid) for childhood TB. In particular, they advocate for rapid initiation of clinical trials in children after the proof of concept and dose-finding (IIa and IIb, respectively) studies carried out in adults. Specific clinical trials are needed to assess efficacy, safety & tolerability of new anti-TB drugs for childhood TB <http://ow.ly/X9wl301VNiR>
Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age
Authors: Michael Pfeilstöcker, Heinz Tüchler, Julie Schanz, Guillermo Sanz, Guillermo Garcia Manero, Francesc Sole, John M. Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus, Hagop M. Kantarjian, Andrea Kuendgen, Alessandro Levis, Luca Malcovati, Mario Cazzola, Jaroslav Cermak, Christa Fonatsch, Michelle Lebeau, Marilyn L. Slovak, Otto Krieger, Michael Luebbert, Jaroslaw P. Maciejewski, M. M. Magalhaes Silvia, Yasushi Miyazaki, Mikkael A. Sekeres, Wolfgang R Sperr, Reinhard Stauder, Sudhir Tauro, Peter Valent, Teresa Vallespi, Arjan A van de Loosdrecht, Ulrich Germing, Detlef Haase, Peter L. Greenberg
Journal: Blood (2013)
Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis
Authors: Jialin Wang, Lydia Gibbert, Sonja Djudjaj, Christina Alidousty, Thomas Rauen, Uta Kunter, Andreas Rembiak, Dieter Enders, Vera Jankowski, Gerald S. Braun, Jürgen Floege, Tammo Ostendorf, Ute Raffetseder
Journal: Kidney International (2016)
Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma.
Authors: Krina K. Patel, Robert Z. Orlowski, Donna M. Weber, Michael Wang, Sheeba K. Thomas, Jatin J. Shah, Francesco Turturro, Raymond Alexanian, Kay Delasalle
Journal: Journal of Clinical Oncology (2012)

8093 Background: In patients with symptomatic multiple myeloma, the clinical features, responses to treatment, and survival times vary. Well established predictors of survival include the International Staging System (ISS), cytogenetic abnormalities, and response to therapy. Long recognized has been the association of high serum lactate dehydrogenase (LDH) with advanced disease and shorter survival. We focused here on the impact of high LDH on staging and prognosis in order to guide the role of recent advances in therapy. Methods: We evaluated 1,247 patients with newly diagnosed, symptomatic myeloma from 10/74 to 7/11. Our goal was to determine the prognostic value of high LDH (&gt;300 IU/L) in relation to ISS stage. We also compared the frequencies of anemia, hypercalcemia, and response to therapy in patients with high LDH with those of patients with Stage III disease and normal LDH values. Results: All 1,139 patients with normal LDH lived significantly longer than the 108 patients with elevated values (47 vs. 16 months, p &lt;.01). LDH was elevated in 9% of all patients, but in 2%, 6%, and 18% of patients with ISS-I, II, and III disease, respectively. Their survival times were also significantly shorter than those of comparable patients in each stage with normal LDH (table). Among the 108 patients with high LDH, the frequencies of hemoglobin &lt;8.5 g/dl (54 vs. 41%, p=.03), and serum calcium&gt;11.5 mg/dl (41 vs. 27%, p&lt;.01) were significantly higher than those of 292 patients with Stage III disease and normal LDH, and the frequency of response to therapy was less (40 vs. 62%, p&lt;.01). Conclusions: Serum lactate dehydrogenase provides a convenient and dependable prognostic indicator in patients with multiple myeloma. An elevated LDH value indicates a poor prognosis regardless of ISS stage, confirming the report by Gkotzamanidou, Terpos, and Dimopoulos et al, and should be included in the definition of stage III disease. Such patients require rapid control of disease with sequential combinations of effective drugs and intensive therapy in order to improve their outcome. [Table: see text]
Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy
Authors: Soon Jae Lee, Yoo-Kyung Cho, Soo-Young Na, Eun Kwang Choi, Sun Jin Boo, Seung Uk Jeong, Hyung Joo Song, Heung Up Kim, Bong Soo Kim, Byung-Cheol Song
Journal: Clinical and Molecular Hepatology (2016)

Some recent studies have found regression of liver cirrhosis after antiviral therapy in patients with hepatitis C virus (HCV)-related liver cirrhosis, but there have been no reports of complete regression of esophageal varices after interferon/peg-interferon and ribavirin combination therapy. We describe two cases of complete regression of esophageal varices and splenomegaly after interferon-alpha and ribavirin combination therapy in patients with HCV-related liver cirrhosis. Esophageal varices and splenomegaly regressed after 3 and 8 years of sustained virologic responses in cases 1 and 2, respectively. To our knowledge, this is the first study demonstrating that complications of liver cirrhosis, such as esophageal varices and splenomegaly, can regress after antiviral therapy in patients with HCV-related liver cirrhosis.
Antibiotics as deep modulators of gut microbiota: between good and evil
Authors: Gianluca Ianiro, Herbert Tilg, Antonio Gasbarrini
Journal: Gut (2016)

The recent increase in our knowledge of human gut microbiota has changed our view on antibiotics. Antibiotics are, indeed, no longer considered only beneficial, but also potentially harmful drugs, as their abuse appears to play a role in the pathogenesis of several disorders associated with microbiota impairment (eg, <i>Clostridium difficile</i> infection or metabolic disorders). Both drug-related factors (such as antibiotic class, timing of exposure or route of administration) and host-related factors appear to influence the alterations of human gut microbiota produced by antibiotics. Nevertheless, antibiotics are nowadays considered a reliable therapy for some non-communicable disorders, including IBS or hepatic encephalopathy. Moreover, some antibiotics can also act positively on gut microbiota, providing a so-called ‘eubiotic’ effect, by increasing abundance of beneficial bacteria. Therefore, antibiotics appear to change, for better or worse, the nature of several disorders, including IBS, IBD, metabolic disorders or liver disease. This reviews aims to address the potential of antibiotics in the development of major non-communicable disorders associated with the alteration of gut microbiota and on newly discovered therapeutic avenues of antibiotics beyond the cure of infectious diseases.
QOL-14QUALITY OF LIFE AND SUPPORTIVE CARE NEEDS OF LONG TERM GLIOMA SURVIVORS AND THEIR FAMILY CAREGIVERS: STUDY PROTOCOL
Authors: Danette Langbecker, Anna Ugalde, David Ashley, Patricia M. Livingston
Journal: Neuro-Oncology (2015)

With improved treatment regimes, an increasing number of glioma patients are becoming long-term cancer survivors. Research has shown a significant number of cancer survivors and their family caregivers experience psychosocial and physical problems, and knowledge of these is essential to develop new interventions or models of care for these groups. This study describes the survivorship care needs and quality of life of long-term glioma survivors or their family caregivers in Australia. A cross-sectional study involving adult glioma survivors (high or low grade glioma, at least 2 years post-diagnosis) and their primary family caregivers across Australia is proposed. We will recruit up to 100 patients and 75 caregivers through study promotion to community and support organisations. Participants will be asked to complete the Functional Assessment of Cancer Therapy (FACT)-Brain, Depression Anxiety Stress Score 21 (DASS-21), Supportive Care Needs Survey (SCNS-34), Self-Administered Comorbidity Questionnaire (SCQ), demographic/medical questions, and open-ended questions regarding the impact of the diagnosis on their activities of daily living, as well as the impact of the disease on their working and social relationships. Caregivers will complete the Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C45), Caregiver Reaction Assessment, Clinical Care Tasks, DASS-21 and SCQ. Data will be analysed and patient-caregiver dyadic data matched. Existing research suggests long-term glioma survivors are likely to have specific survivorship care needs regarding cognition, neurological deficits, and psychological well-being. This project will provide recommendations for interventions to address the unmet needs of people living with glioma and their caregivers.
Folic Acid Supplementation and Cardiovascular Diseases—Reply
Authors: Lydia A. Bazzano, Kristi Reynolds, Kevin N. Holder, Jiang He
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients.
Authors: R. Romeo, A. Sangiovanni, M. Iavarone, S. Vavassori, C. Della Corte, M. Colombo
Journal: Journal of Clinical Oncology (2010)

4119 Background: Highly specific and sensitive serum markers for hepatocellular carcinoma (HCC) are largely awaited for diagnosis of HCC. Serum alfafetoprotein (AFP) Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) are likely candidates. Aim:to define sensitivity and specificity of AFP, AFP-L3%, DCP for the diagnosis of HCC in cirrhotic patients. Methods: Serum corresponding to a random series of cirrhotic patients with (N=86) or without (N=38) HCC were tested for AFP (ng/mL), AFP-L3% (percent) and DCP (ng/mL) by a new microchip capillary electrophoresis on the μ TAS Wako i30 autoanalyzer (Wako Pure Chemical Industries, Ltd., Japan). The lowest measurable value for AFP-L3% and DCP was 0.3, and 0.1, respectively. Results: 124 patients, mean age 62 (±10.2) yrs, 94 (76%) males, all Child-Pugh A, were enrolled. The median (25th-75th quartile) AFP, AFP-L3% and DCP values were significantly higher in HCC than in cirrhosis: AFP 17 (9-49) vs. 3.9 (2.2-8.0) p< 0.05, AFP-L3% 7.5 (5.5-11.4) vs. 0.5 (0.5-6.7) p < 0.05, DCP 1.07 (0.37-4.14) vs. 0.26 (0.16-0.37, p< 0.05). The Table reports the sensibility and specificity of the three markers. The combination of the three tests, at cutoff values of 7% for AFP-L3% 0.75 ng/ml for DCP and 20 ng/mL for AFP by ROC analysis are reported in the Table. Conclusions: The combined application of AFP-L3% and DCP increases the diagnostic accuracy for HCC. in patients with cirrhosis. The diagnostic accuracy of this approach needs to be validate in low prevalence series like cirrhotic patients under surveillance. Analyte Cutoff Sensitivity (%) Specificity (%) Analyte Sensitivity (%) Specificity (%) AFP 20 ng/mL 46.5 86.8 AFP 46.5 86.8 AFP-L3% 5% 77.9 52.6 AFP-L3% 55.8 78.9 7% 55.8 78.9 DCP 55.9 92.1 10% 31.4 89.5 AFP+AFP-L3% 65.1 71.1 DCP 0.5 ng/mL 66.3 84.2 AFP+DCP 69.8 78.9 0.75 ng/mL 55.8 92.1 AFP-L3%+DCP 76.7 76.3 2.5 ng/mL 20.9 100 AFP+AFP-L3% 79.1 68.4 7.5 ng/mL 15.1 100 No significant financial relationships to disclose.
Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro: Clinical Meaning and Activation Of The NFkB Pathway
Authors: Sandrine Poglio, Xavier Cahu, Benjamin Uzan, Hélène Lapillonne, Thierry Leblanc, André Baruchel, Judith Landman-Parker, Arnaud Petit, Frederic Baleydier, Sophie Amsellem, Paola Ballerini, Françoise Pflumio
Journal: Blood (2013)
Dendritic Cells and CD8+ Lymphocytes in Early Mycosis Fungoides.
Authors: Gaia Goteri, Alessandra Filosa, Serena Rupoli, Stefano Pulini, Angela Tassetti, Anna Rita Scortechini, Roberta Capretti, Daniela Stramazzotti, Giorgio Mozzicafreddo, Anna Maria Offidani, Lorenzo Morresi, Sergio Lanari, Guidalberto Fabris, Pietro Leoni
Journal: Blood (2004)
Dynamic Convergent Evolution Drives the Passage Adaptation across 48 Years’ History of H3N2 Influenza Evolution
Authors: Hui Chen, Qiang Deng, Sock Hoon Ng, Raphael Tze Chuen Lee, Sebastian Maurer-Stroh, Weiwei Zhai
Journal: Molecular Biology and Evolution (2016)

Influenza viruses are often propagated in a diverse set of culturing media and additional substitutions known as passage adaptation can cause extra evolution in the target strain, leading to ineffective vaccines. Using 25,482 H3N2 HA1 sequences curated from Global Initiative on Sharing All Influenza Data and National Center for Biotechnology Information databases, we found that passage adaptation is a very dynamic process that changes over time and evolves in a seesaw like pattern. After crossing the species boundary from bird to human in 1968, the influenza H3N2 virus evolves to be better adapted to the human environment and passaging them in embryonated eggs (i.e., an avian environment) leads to increasingly stronger positive selection. On the contrary, passage adaptation to the mammalian cell lines changes from positive selection to negative selection. Using two statistical tests, we identified 19 codon positions around the receptor binding domain strongly contributing to passage adaptation in the embryonated egg. These sites show strong convergent evolution and overlap extensively with positively selected sites identified in humans, suggesting that passage adaptation can confound many of the earlier studies on influenza evolution. Interestingly, passage adaptation in recent years seems to target a few codon positions in antigenic surface epitopes, which makes it difficult to produce antigenically unaltered vaccines using embryonic eggs. Our study outlines another interesting scenario whereby both convergent and adaptive evolution are working in synchrony driving viral adaptation. Future studies from sequence analysis to vaccine production need to take careful consideration of passage adaptation.
Both Host-Type and Donor-Type Mast Cells Protect Against Acute Graft-Versus-Host Disease
Authors: Raita Araki, Hideaki Maeba, Rie Kuroda, Shintaro Mase, Toshihiro Fujiki, Yasuhiro Ikawa, Shoichi Koizumi, Akihiro Yachie, Ryosei Nishimura
Journal: Blood (2013)
Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma
Authors: Hiroshi Fujiwara, Takashi Ishida, Kisato Nosaka, Naoya Taira, Yasunobu Abe, Yoshitaka Imaizumi, Yukiyoshi Moriuchi, Tatsuro Jo, Kenichi Ishizawa, Kensei Tobinai, Kunihiro Tsukasaki, Shigeki Ito, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, Shuichi Midorikawa, Wanda Ruiz, Tomoko Ohtsu
Journal: Blood (2015)
The Power to Heal
Authors: Samantha Hsieh, Eric Laurent Maranda, Tarek Salih, Austin Nguyen, Amanda M. Marsh, Joaquin J Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Biomimicking Platelet–Monocyte Interactions as a Novel Targeting Strategy for Heart Healing
Authors: Bill Cheng, Elsie K. W. Toh, Kun‐Hung Chen, Yuan‐Chih Chang, Che‐Ming J. Hu, Han‐Chung Wu, Lee‐Young Chau, Peilin Chen, Patrick C. H. Hsieh
Journal: Advanced Healthcare Materials (2016)

In patients who survive myocardial infarction, many go on to develop congestive heart failure (CHF). Despite ongoing efforts to develop new approaches for postinfarction therapy, there are still no effective therapeutic options available to CHF patients. Currently, the delivery of cardioprotective drugs relies entirely on passive uptake via the enhanced permeability and retention (EPR) effect which occurs in proximity to the infarction site. However, in ischemic disease, unlike in cancer, the EPR effect only exists for a short duration postinfarction and thus insufficient for meaningful cardioprotection. Splenic monocytes are recruited to the heart in large numbers postinfarction, and are known to interact with platelets during circulation. Therefore, the strategy is to exploit this interaction by developing platelet-like proteoliposomes (PLPs), biomimicking platelet interactions with circulating monocytes. PLPs show strong binding affinity for monocytes but not for endothelial cells in vitro, mimicking normal platelet activity. Furthermore, intravital multiphoton imaging shows that comparing to plain liposomes, PLPs do not aggregate on uninjured endothelium but do accumulate at the injury site 72 h postinfarction. Importantly, PLPs enhance the targeting of anti-inflammatory drug, cobalt protoporphyrin, to the heart in an EPR-independent manner, which result in better therapeutic outcome.
Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses
Authors: Yvan J-F Hutin, Stefan Z Wiktor
Journal: Gut (2016)

In May 2016, the World Health Assembly, the governing body of WHO, endorsed the first-ever global hepatitis strategy.1 This document, termed the Global Health Sector Strategy on Viral Hepatitis (GHSS-VH), proposes ambitious prevention and treatment targets with the ultimate goal of eliminating hepatitis as a public health threat by 2030. The GHSS-VH defines elimination as a 90% reduction in incidence of chronic HBV and HCV infections and a 65% reduction in hepatitis-related mortality. Achieving the goals of the global strategy will require scaling up prevention and treatment services, which in turn will require increases in financial resources and political commitment. In addition, national health planners will need to decide how best to allocate these resources so that they have maximal impact. A solid understanding of the epidemiology of hepatitis infection in the country, in particular identifying groups at highest risk of infection and those at highest risk of death should be the basis of a sound national treatment plan that can meet the incidence and mortality goals of GHSS-VH.

In this issue, Scott et al 2 developed a mathematical model to study which treatment strategies would most effectively and efficiently eliminate hepatitis C in Australia, based on the WHO strategy's goals. As in most high-income countries, HCV infection …
AMIの引き金:環境温度はAMIの発症に関係する:Takashima AMI研究
Authors: Turin Tanvir Chowdhury, Kita Yoshikuni, Rumana Nahid, Takashima Nayouki, Okayama Akira, Nakamura Yasuyuki, Ueshima Hirotsugu
Journal: Circulation (2009)
Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity
Authors: Alison R Walker, Hongyan Wang, Rebecca Klisovic, Katherine Walsh, Sumithira Vasu, Ramiro Garzon, Steven M. Devine, Amy Drake, William Blum, Guido Marcucci
Journal: Blood (2013)